Icariin Inhibits NF-κB Signaling in Asthmatic Lung Epithelium by Promoting Nrf2 Signaling

Area of Science:

• * Pharmacology and Toxicology
• * Respiratory Medicine
• * Molecular Biology

Background:

• * Current asthma treatments like glucocorticoids and beta2-agonists have limitations due to drug tolerance and side effects.
• * Oxidative stress is a key pathological feature of asthma not targeted by current frontline therapies.
• * Icariin, derived from Epimedium, exhibits anti-oxidative stress properties and has shown potential in preclinical asthma models.

Purpose of the Study:

• * To investigate the anti-oxidative stress mechanism of Icariin in asthmatic airway epithelium.
• * To determine if Icariin inhibits NF-κB signaling by promoting Nrf2 expression in asthma.
• * To explore the therapeutic potential of Icariin for asthma by targeting oxidative stress.

Main Methods:

• * Analysis of oxidative/antioxidant factor imbalance in asthmatic patients and a mouse model.
• * In vivo studies using an OVA-induced allergic asthma mouse model.
• * In vitro studies using the human bronchial epithelial cell line (HBE) to explore Icariin's mechanism.

Main Results:

• * Asthmatic patients and mice exhibited an imbalance of oxidative/antioxidant factors.
• * Icariin alleviated airway inflammation and restored oxidative/antioxidant balance in asthmatic mice.
• * Icariin promoted Nrf2 expression and inhibited NF-κB signaling in both mice and HBE cells, with Nrf2 knockdown weakening this effect.

Conclusions:

• * Icariin exerts anti-asthmatic effects by promoting Nrf2 activation, which subsequently inhibits NF-κB signaling.
• * The mechanism involves targeting oxidative stress, independent of DNA methylation of Keap-1 or Nrf2.
• * Icariin represents a promising therapeutic candidate for asthma by modulating the Nrf2/NF-κB pathway.